Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item8.01.Other Events.
On April29, 2017, Anita Nelson, MD, Professor and Chair,
Obstetrics and Gynecology, College of Osteopathic Medicine of the
Pacific, and Co-Principal Investigator of the Agile
Therapeutics,Inc., SECURE Phase 3 clinical trial made a
presentation entitled An Update on Hormonal Contraception and
The Changing U.S. Population at the 2017 Academy of the
Womens Health Congress on April29, 2017 at 8:00am ET at the
Crystal Gateway Marriott in Arlington, VA. The presentation
focused on real-world contraceptive study design and outcomes.
The presentation also included data from the Phase 3 clinical
trial evaluating Twirla, also known as the SECURE clinical trial.
SECURE was a one-year, multicenter, single-arm, open-label trial
that evaluated the safety, efficacy and tolerability of Twirla in
2032 healthy women, aged 18 and over, at 102 experienced
investigative sites across the United States. Agile announced
top-line results of the SECURE clinical trial in January2017.
The Company plans to resubmit its new drug application (NDA) for
Twirla by the end of the second quarter of 2017.
Copies of the presentation are attached hereto as Exhibit99.1 and
is hereby incorporated by reference herein.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Agile Therapeutics,Inc. Presentation dated April29, 2017. |
About Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period. Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information
Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session down -0.02 at 3.58 with 223,862 shares trading hands.